AOD-9604 for bodybuilders: fat-loss claims under review
AOD-9604 is often described as a selective cutting aid. Its clinical development history does not support treating it as a proven way to lose fat while preserving bodybuilding performance.
By PurePeptideHub Editorial Team · Updated . Educational source review; independent clinical review pending.
The evidence behind the claim
FDA’s review describes the unsuccessful obesity-development program, including the 24-week OPTIONS study. The evidence does not establish a bodybuilding benefit.
References: [1]
Obesity research is not a cutting study
An obesity trial and a bodybuilding preparation differ in baseline body composition, energy intake, training and desired outcomes. Even a positive weight result would not establish preserved lean mass, strength or contest readiness in lean athletes. Here, the reviewed obesity evidence itself did not establish the marketed benefit.
What evidence a bodybuilding claim would need
Look for measured fat mass, lean mass and performance alongside weight, with a suitable comparator and adverse-event reporting. A mechanism described as lipolytic is not a substitute for those outcomes. Study registration, trial results and sales claims should be read separately.
Sources and further reading
Important Considerations
- !Match the exact compound, route, study population and measured outcome before applying a research finding.
- !This source review does not establish an individual treatment plan. Discuss clinical questions with a qualified healthcare professional.
Frequently Asked Questions
Does being a growth-hormone fragment make AOD-9604 equivalent to GH?
No. A fragment is a distinct molecule. It cannot inherit all the effects, evidence or medical uses of the parent hormone.
Can the old obesity trials establish an injectable cutting schedule?
No. The trial setting and formulations do not validate a bodybuilding regimen, and the FDA review describes major limitations in the efficacy evidence.